

Technology Advisory Committee D Interests Register

Topic: Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]

Publication Date: 15 April 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Will Sullivan	Committee member	Direct – financial	<p>- Between March 2024 and August 2024, Will was part of the team providing consultancy support to Novartis, helping the team to prepare for the US launch of asciminib for newly diagnosed chronic myelogenous leukaemia, for which the company Will is employed by received payment.</p> <p>- Will was considered conflicted for the ongoing appraisal of Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] (Incyte, rather than Novartis, are the manufacturer company in that indication), owing to Will being part of the EAG for that appraisal up to the point of EAG report completion.</p>	16/10/2024 12/02/2025	It was agreed that Dr Sullivan's declarations would not prevent them from participating in discussions on this appraisal.
Fiona Dignan	Clinical expert	Direct – non-financial	- Fiona is a national specialty advisor for blood and marrow transplantation (since April 2020)	06/11/2024	It was agreed that Fiona's declaration would not prevent them from

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> - Fiona is secretary of the British Society for Blood and Marrow Transplantation (since 2018) - Fiona is co-chair of the delivering for patients working party of the UK Stem Cell Forum (since 2019) - Fiona was previously involved in the REACH 2+ 3 clinical trials of ruxolitinib for GVHD but these have now closed. 		providing expert advice to the committee.
Donal McLornan	Clinical expert	Direct – financial	<ul style="list-style-type: none"> - Novartis Pharmaceuticals: Advisory boards, speaker fees and travel to conferences (American Society of Haematology and EBMT) within the last 12 months. - GSK: Advisory boards and speaker fees within the last 12 months 	06/11/2024	It was agreed that Donal's declaration would not prevent them from providing expert advice to the committee.
Donal McLornan	Clinical expert	Direct – non-financial	- Co-Chair of the EBMT scientific council and Chair of the Chronic Malignancies Working Party of the EBMT	06/11/2024	It was agreed that Donal's declaration would not prevent them from providing expert advice to the committee.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> - Sub-Investigator on MAST study (Faecal Microbiome Transfer pre-emptively to reduce GVHD) - Sub-Investigator on MOTD study (different immunosuppressive strategies to reduce GVHD) 		